InsiderTrades

Form 4 for OKUR OnKure Therapeutics, Inc.

Accepted 2024-10-08 00:00:00 ET · period of report 2024-10-04 · accession 0001415889-24-024912 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-10-08 2024-10-04 OKUR Carruthers R Michael Dir A - Grant — +4,939 874 New —
DM 2024-10-08 2024-10-04 OKUR Carruthers R Michael Dir A - Grant $0.00 +18.4K 15.3K New $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Class A Common Stock 2024-10-04 A A 4,065 — 4,939 D — — (F2) These securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock upon the meeting of both a "Service-Based Requirement" and a "Liquidity Event Plus Service Requirement." 1/16th of the RSUs met the "Service-Based" requirement on June 20, 2023 and 1/16th of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the Reporting Person continuing as a service provider through each such date. At the effective time of the Merger, each RSU of OnKure was assumed by, and converted into an RSU award of, Reneo covering such number of shares of Reneo Class A Common Stock determined by multiplying the number of shares of OnKure preferred stock subject to the RSU award by a designated exchange ratio (rounded down to the nearest whole share). (F1) Pursuant to the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo Pharmaceuticals, Inc. ("Reneo"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo ("Merger Sub I"), and OnKure, Inc. ("OnKure"), on October 4, 2024, Merger Sub I merged with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the "Merger"). At the effective time of the Merger, each share of OnKure common stock and Series C preferred stock was converted into the right to receive a number of shares of Reneo Class A Common Stock determined by multiplying each such share by a designated exchange exchange ratio (rounded down to the nearest whole share). After completion of the Merger, the combined company was renamed "OnKure Therapeutics, Inc." and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol "OKUR."
2 Common Class A Common Stock 2024-10-04 A A 874 — 874 D — — (F1) Pursuant to the Agreement and Plan of Merger, dated as of May 10, 2024 (the "Merger Agreement"), by and among Reneo Pharmaceuticals, Inc. ("Reneo"), Radiate Merger Sub I, a wholly owned subsidiary of Reneo ("Merger Sub I"), and OnKure, Inc. ("OnKure"), on October 4, 2024, Merger Sub I merged with and into OnKure, with OnKure surviving the merger as a wholly-owned subsidiary of Reneo (the "Merger"). At the effective time of the Merger, each share of OnKure common stock and Series C preferred stock was converted into the right to receive a number of shares of Reneo Class A Common Stock determined by multiplying each such share by a designated exchange exchange ratio (rounded down to the nearest whole share). After completion of the Merger, the combined company was renamed "OnKure Therapeutics, Inc." and the Class A Common Stock of the combined company trades on The Nasdaq Stock Market under the symbol "OKUR."
3 Derivative Stock Option (right to buy) 2024-10-04 A A 1,760 — 1,760 D $21.20 · — to 2031-07-06 1,760 Class A Common Stock (F4) Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent). (F3) All of the shares subject to this option are fully vested and exercisable as of the date hereof.
4 Derivative Stock Option (right to buy) 2024-10-04 A A 1,324 — 1,324 D $13.99 · — to 2033-08-29 1,324 Class A Common Stock (F4) Each OnKure stock option that was outstanding immediately prior to the effective time of the Merger was assumed by Reneo and became an option to acquire, on the same terms and conditions as were applicable to such OnKure stock option immediately prior to the effective time of the Merger, a number of shares of Reneo Class A common stock equal to the number of shares of OnKure common stock subject to the unexercised portion of the OnKure stock option immediately prior to the effective time of the Merger, multiplied by a designated exchange ratio (rounded down to the nearest whole share). The exercise price per share for the options is equal to the exercise price per share of such OnKure stock option immediately prior to the effective time of the Merger divided by the exchange ratio (rounded up to the nearest whole cent). (F5) 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person continuing as a service provider through each such date.
5 Derivative Stock Option (right to buy) 2024-10-04 A A 15,300 $0.00 15,300 D $18.20 · — to 2034-10-03 15,300 Class A Common Stock (F6) 1/36th of the shares subject to the option shall vest on November 4, 2024 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.